Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

223.58 -5.24 (-2.29%)
Streaming Delayed Price Updated: 11:17 AM EDT, Jul 3, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
BIIB STOCKHOLDERS: Lead Plaintiff Deadline Approaching in Biogen Inc. Class Action; Contact Robbins LLP
From Robbins LLP
Via GlobeNewswire
Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
The company is on deck to rival Biogen and Eisai's Leqembi. 
Via Investor's Business Daily
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Forecasting The Future: 19 Analyst Projections For Biogen
Via Benzinga
Biogen Completes Acquisition of Human Immunology Biosciences
From Biogen Inc.
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
This Is Massive News for Eli Lilly Investors
A panel of advisors to the Food and Drug Administration (FDA) recently recommended Eli Lilly's Alzheimer's candidate. 
Via The Motley Fool
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Biogen
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Biogen To Contact Him Directly To Discuss Their Options 
From Faruqi & Faruqi LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, Fastly, and NIKE and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
“LEQEMBI®” (Lecanemab) for the Treatment of Alzheimer’s Disease Launched in China
China is the Third Country to Launch LEQEMBI Following the United States and Japan 
From Biogen Inc.
Via GlobeNewswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
BIOGEN INC. (NASDAQ: BIIB) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Biogen Inc. Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Alzheimer's Drug Stocks: Investing in Eli Lilly, Biogen, Roche
The race to develop effective Alzheimer's treatments presents significant opportunities and inherent risks for healthcare investors. 
Via MarketBeat
Exposures Product Safety
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines
Biotechnology firm Moderna Inc. (NASDAQ: MRNA) made mainstream headlines during the pandemic for its COVID-19 vaccines. Moderna is focused on messenger RNA 
Via MarketBeat
Exposures COVID-19
BIOGEN INC. (NASDAQ: BIIB) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Biogen Inc.
From Bernstein Liebhard LLP
Via GlobeNewswire
BIIB INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Biogen, Inc. Investors with Substantial Losses Have Opportunity to Lead Case
From Robbins Geller Rudman
Via Business Wire
The 3 Best Healthcare Stocks to Buy in June 2024
Aging populations and changing lifestyles mean healthcare is a secular story that these best healthcare stocks to buy will capitalize on. 
Via InvestorPlace
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Biogen, Charge, and Fastly and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Kirby McInerney LLP Reminds Biogen, Inc. (BIIB) Investors of Class Action Filing and Encourages Investors to Contact the Firm
From Kirby McInerney LLP
Via GlobeNewswire
4 Best Stocks to Buy and 3 Best Stocks to Sell: June 2024
Consider making moves in these securities, each of which has news that is impacting their share price either positively or negatively. 
Via InvestorPlace
BIIB Investors Have Opportunity to Lead Biogen Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
Eli Lilly's donanemab for Alzheimer's disease garners positive FDA committee verdict, prompting analyst's bullish outlook amid comparisons to Biogen's Leqembi. 
Via Benzinga
Exposures Product Safety
Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
An FDA panel unanimously backed Eli Lilly's Alzheimer's drug, but shares of Lilly and its rivals fell Tuesday. 
Via Investor's Business Daily
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
EQNX::TICKER_START (NASDAQ:TLSA),(NYSE:LLY),(OTCQX:RHHBY),(NASDAQ:BIIB),(NASDAQ:TGTX) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures Product Safety
Global Multiple Sclerosis Drugs Market Size Projected to Reach $38 Billion By 2032 as Demand on R&D for Developing Innovative Drugs Rises
From FN Media Group LLC
Via GlobeNewswire
Why Is Eli Lilly Stock Trading Higher Premarket Tuesday?
Shares of Eli Lilly surged as an FDA advisory committee endorsed donanemab, an Alzheimer's treatment shown to significantly impact early-stage patients. The drug's benefits outstripped risks, setting... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 5 6 7 8 9
...
45 46 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.